Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 136,055,552
  • Shares Outstanding, K 2,262,690
  • Annual Sales, $ 26,145 M
  • Annual Income, $ 3,439 M
  • 60-Month Beta 0.71
  • Price/Sales 5.26
  • Price/Cash Flow 13.84
  • Price/Book 2.80
Trade BMY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 1.49
  • Number of Estimates 6
  • High Estimate 1.53
  • Low Estimate 1.44
  • Prior Year 1.17
  • Growth Rate Est. (year over year) +27.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.61 +4.37%
on 10/06/20
62.42 -3.67%
on 10/19/20
+1.14 (+1.93%)
since 09/23/20
3-Month
56.90 +5.68%
on 09/21/20
64.27 -6.44%
on 08/12/20
+0.26 (+0.43%)
since 07/23/20
52-Week
45.76 +31.40%
on 03/23/20
68.34 -12.01%
on 01/22/20
+5.36 (+9.79%)
since 10/23/19

Most Recent Stories

More News
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

JNJ : 145.24 (+0.11%)
PFE : 38.18 (+2.00%)
GILD : 60.79 (+0.20%)
MRK : 79.83 (+0.78%)
LLY : 142.38 (+0.52%)
BMY : 60.13 (-1.04%)
AMGN : 227.16 (-0.36%)
ABBV : 84.34 (+0.04%)
XLV : 107.82 (+0.37%)
VHT : 209.85 (+0.46%)
IYH : 232.62 (+0.37%)
FHLC : 54.18 (+0.50%)
Novartis (NVS) Gets Orphan Drug Tag for Huntington's Disease Drug

Novartis (NVS) gets orphan drug designation for branaplam (LMI070) in Huntington's disease.

PFE : 38.18 (+2.00%)
MRK : 79.83 (+0.78%)
NVS : 84.43 (+0.02%)
BMY : 60.13 (-1.04%)
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?

Investors will focus on whether Amgen's (AMGN) sales have recovered in the third quarter from the COVID-19 effect.

RHHBY : 41.0300 (+0.20%)
INCY : 89.69 (-0.88%)
BMY : 60.13 (-1.04%)
AMGN : 227.16 (-0.36%)
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

JNJ : 145.24 (+0.11%)
PFE : 38.18 (+2.00%)
GILD : 60.79 (+0.20%)
MRK : 79.83 (+0.78%)
LLY : 142.38 (+0.52%)
BMY : 60.13 (-1.04%)
AMGN : 227.16 (-0.36%)
ABBV : 84.34 (+0.04%)
XLV : 107.82 (+0.37%)
VHT : 209.85 (+0.46%)
IYH : 232.62 (+0.37%)
FHLC : 54.18 (+0.50%)
Keloid Treatment Market Opportunities And Strategies To 2025: COVID-19 Impact and Recovery

Global share consists of several players including Pacific World Corporation, Revitol Corporation Inc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, Novartis AG, Renovo Group plc., Valeant Pharmaceuticals...

AVMXY : 7.8900 (+9.13%)
BMY : 60.13 (-1.04%)
GALE : 0.26 (-7.14%)
GSK : 35.29 (+0.57%)
NVS : 84.43 (+0.02%)
PRGO : 45.62 (+0.31%)
SNOA : 8.03 (+1.26%)
VRX.TO : 30.80 (-3.33%)
Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II

Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.

RHHBY : 41.0300 (+0.20%)
BMY : 60.13 (-1.04%)
EBS : 96.11 (-1.58%)
PRTA : 11.45 (-3.13%)
M&A ETF (MNA) Hits New 52-Week High

This M&A ETF hits a new 52-week high. Are more gains in store for this ETF?

COP : 32.54 (+1.97%)
CXO : 46.97 (+2.02%)
BMY : 60.13 (-1.04%)
MNA : 34.10 (-0.23%)
MYOK : 222.97 (+0.37%)
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market

, /PRNewswire/ -- Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies. Adverse effects, such as recurrence of cancer and organ failure, associated with...

ATNM : 11.28 (-4.57%)
AZN : 52.00 (+0.08%)
BMY : 60.13 (-1.04%)
MRK : 79.83 (+0.78%)
NWBO : 1.9800 (+4.21%)
Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC

Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.

PFE : 38.18 (+2.00%)
MRK : 79.83 (+0.78%)
EXEL : 22.29 (+2.11%)
BMY : 60.13 (-1.04%)
ImmunoGen (IMGN) Inks Mirvetuximab Development Deal in China

ImmunoGen (IMGN) grants exclusive rights to Huadong Medicine for development and commercialization of mirvetuximab soravtansine in Greater China.

BMY : 60.13 (-1.04%)
JAZZ : 150.26 (-0.61%)
IMGN : 5.46 (-0.73%)
ABBV : 84.34 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products. It offers products which includes hematology, oncology, cardiovascular and immunology. Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, is based in...

See More

Key Turning Points

2nd Resistance Point 61.62
1st Resistance Point 60.88
Last Price 60.13
1st Support Level 59.73
2nd Support Level 59.33

See More

52-Week High 68.34
Last Price 60.13
Fibonacci 61.8% 59.71
Fibonacci 50% 57.05
Fibonacci 38.2% 54.39
52-Week Low 45.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar